June 20th 2025
The FDA has extended the review of ruxolitinib for atopic dermatitis in children 2 to 11 years to September 2025 to evaluate new CMC data.
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More